Advertisement

Picture EBD Group BioPharm America 2018 Boston Speakers 600x60px
Document › Details

Agilent Technologies Inc.. (7/16/18). "Press Release: Agilent Technologies Completes Acquisition of Ultra Scientific Assets". Santa Clara, CA.

Organisation Organisation Ultra Scientific Inc.
Products Product reference materials / standards (analytics/diagnostics)
  Product 2 laboratory equipment and instruments
Index term Index term Ultra Scientific–Agilent: investment, 201805– acquisition of all business assets €na of Ultra Scientific by Agilent
Persons Person Cohan, Steve (Agilent 201807 VP + General Manager of Supplies division)
  Person 2 Notaney, Stefanie (Agilent 201801)
     


Agilent Technologies, Inc. (NYSE: A) today announced that it has completed the acquisition of the business assets of ULTRA Scientific, Inc., a leading provider of chemical standards and certified reference materials.

Agilent identified chemical standards as a key expansion area that will enable Agilent to enhance the customer experience by providing complete workflow solutions. ULTRA Scientific's extensive catalog of chemical standards are critical to analytical laboratory workflows and help customers qualify the performance of their methods to validate and quantitate results. ULTRA Scientific serves laboratory professionals in key end markets including environmental, food, forensics, pharmaceutical, chemical and energy, and academia and government.

"Agilent was one of ULTRA Scientific's largest customers so we have great confidence in the team and solutions," said Steve Cohan, vice president and general manager of Agilent's Supplies Division. "We look forward to combining the teams, and the new opportunities we will have to leverage our combined strengths and create significant value for our customers as we work towards our goal of creating complete workflow solutions."

Financial terms of the deal are not being disclosed.

More information on ULTRA Scientific's products and solutions is available at www.ultrasci.com.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at www.agilent.com.


Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the capabilities and expertise the acquisition brings, the ability to supply industry requirements and acceleration of growth. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, the ability to integrate Ultra Scientific's operations with Agilent's, meet customer expectations and realize efficiencies from the combined businesses. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended April 30, 2018. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.


Editorial Contacts

Victoria Wadsworth-Hansen (Business)
+1 408 553 2005
+ 45 29336980
victoria.wadsworth-hansen@agilent.com

Stefanie Notaney (Enterprise)
+1 408 345 8955
stefanie.notaney@agilent.com


Investor Contact

Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com

   
Record changed: 2018-07-25

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px




» top